TapImmune Inc. (TPIV) Announces the Appointment of Sherry Grisewood to the Board of Directors
SEATTLE, March 20, 2013 /PRNewswire/ -- TapImmune Inc. (OTCQB: TPIV) has pleasure in announcing the appointment of Sherry Grisewood, CFA to the Board of Directors. She has over 25 years securities industry experience in a range of investment banking, advisory and research-related activities. She currently has a senior banking and banking analytical role at Dawson James Securities. Prior to joining Dawson James, she was Managing Director, Lifesciences and Technology Banking for Tripoint Global Equities. Sherry served as Senior Life Sciences Banker at Jesup & Lamont Securities Corp. and as an independent strategic advisor and consultant for several investment banks over the prior 12 year period. She has participated in over 50 transaction-related projects worldwide involving initial public offerings, secondary offerings, PIPE's, private equity, M&A and licensing transactions in the life sciences sector. Prior to consulting for investment banks, Sherry served as Director of Research for several mid-tier brokerage companies and a leading independent investment research company. She has been an advisor to TapImmune since 2011.
Sherry has a Bachelor of Science degree in Life Science (Highest Honors) from Ramapo College of New Jersey. She is a member of the American Society of Gene and Cell Therapy, the Tissue Engineering and Regenerative Medicine Society International, the Society of Biomaterials, the CFA Institute and the NY Society of Security Analysts.
Dr Glynn Wilson, Chairman & CEO of TapImmune, stated, "We welcome the appointment of Sherry to the Board. Sherry's experience in investment banking and strategic transactions in emerging life sciences technology platforms will be of significant value to TapImmune as it expands its clinical studies and technologies and enters strategic collaborations for its core immunotherapy platforms."
Sherry Grisewood added "I am honored to be appointed to TapImmune's Board. Immunotherapy is finally emerging at the forefront of new strategies to treat primary and recurrent cancer. TapImmune's technology uniquely positions the Company to be an important contributor to the advancement of this field. I am very excited about having an active role in helping TapImmune achieve clinical and commercial success in bringing immunotherapy to the bedside."
About TapImmune Inc.
TapImmune is a clinical-stage immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's ("Prime" and "Boost") approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system. A Phase I study at the Mayo Clinic is currently evaluating the safety and immune responses of a set of proprietary HER2/neu antigens that will be part of the "Prime" for a HER2/neu breast cancer vaccine. The Company is also exploiting the emerging field of vaccinomics for the development of vaccines applicable to a broad patient population. TapImmune's immunotherapy technologies are also aimed at the prevention of emerging viral pathogens for pandemics and biodefense.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Glynn Wilson, Ph.D.
Chairman & CEO
SOURCE TapImmune Inc.